Previous 10 | Next 10 |
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an exclusive option agreement with the University of Southern California (“USC”). Signed June 11, 2024, the o...
TORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it ente...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received approval for its METAL-2 trial to be conducted in the United States. The appr...
TORONTO, ON / ACCESSWIRE / June 4, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confirms that it has rece...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, announced that the U.S. District Court for the Eastern District of Pennsylvania has confir...
TORONTO, ON / ACCESSWIRE / May 31, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on May 29,...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) i...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an investor relations services agreement with IR Agency LLC. According to the announcement, the agreement, which was effec...
TORONTO, ON / ACCESSWIRE / May 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confirms the submission o...
TORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it has entered into an investor...
News, Short Squeeze, Breakout and More Instantly...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has been featured in a news report published by 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of finan...
Denver, Colorado--(Newsfile Corp. - July 25, 2024) - 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting functional beverage market developments, featuring FSD Pharma (NASDAQ: HUGE...
2024-07-25 08:16:52 ET DENVER, Colo., Jul 25, 2024 ( 247marketnews.com )- Coca-Cola (NYSE: KO ) , FSD Pharma (NASDAQ: HUGE ), and Celsius Holdings, Inc. (NASDAQ: CELH ) Sometimes, there are some winning streaks that are so strong that even...